As usual with me it's about the "what ifs." Like what if big pharma is now involved? "Major changes" are different management setup and different website ownership/management. Increase in trading activity and price coincide with the dates of these developments. Not your typical OTC stock with a patent, Memorial Sloan Kettering a shareholder and their lead researcher also a director and shareholder. https://www.mskcc.org/research-areas/labs/robert-benezra
Some info on their patent
New York City Based Biotech AngioGenex Inc. Reports on Recent Scientific Presentations and Publications
Source Press Release
Tags Trial Results, Pre-clinical, Oncology
Date February 18, 2014
NEW YORK, February 18, 2014 -AngioGenex, Inc. (AGGX, PK) is a New York based biopharmaceutical company that discovers and develops novel and impactful drugs that target proteins (Id proteins) present in cancer but not healthy tissue. The Company's lead drug (Idantirx , AGX51 ) lowers the concentration of these proteins and causes a significant anti-cancer effect. The approval of the patent covering this drug
, and the recent filings of additional patents covering new data on potentially broader use, allow the Company to share findings including the anti-cancer action of this remarkable molecule.
At the American Association of Cancer Research meeting in 2013, the Company reported on the ability of Idantirx to retard the growth and metastasis of implanted human breast cancer tumors in mice. Other experiments in cancer cells demonstrated that Idantirx ’s suppression of the Id proteins resulted in restoration of key anti-growth mediators and cell cycle control. Additional findings with Idantirx established the potential usefulness of the drug in combination with the widely prescribed chemotherapeutic drug, paclitaxel (Taxol ®). These studies were partially supported by an SBIR grant awarded by the National Cancer Institute to the Company in 2011 to expedite development of Idantirx .
In 2013, a chapter written by the AGX technical team appeared in the Annual Reports in Medicinal Chemistry. It reviewed the chemical and biological aspects of inhibiting protein-protein interaction and the new and unique procedures used in the discovery of Idantirx . “Targeting Protein–Protein Interactions to Treat Cancer—Recent Progress and Future Directions,” in Annual Reports in Medicinal Chemistry (Volume 48, 2013, Pages 227–245): sciencedirect.com.
The prestigious Nature Reviews Cancer published an article about the Id Proteins prepared by members of the AGX Cancer Scientific Advisory Board (SAB) in its February, 2014 issue.
Recently, Dr. Glenn Stoller a member of the AGX Ocular Scientific Advisory Board, reported significant advances in the Company's ocular program with Idantirx at the national Bascom-Palmer Symposium on Angiogenesis, Exudation, and Degeneration. Dr. Stoller provided experimental results showing that Idantirx is highly active in the animal model of human age-related macular degeneration that predicted the clinical success of Lucentis (Genentech ) and Eylea (Regeneron ).
Reflecting on the experimental results with Idantirx , Dr. Robert Benezra, the discoverer of the Id proteins and genes and head of the company's Scientific Advisory Board stated: "After almost a decade of research, we have an experimentally proven molecule with potent anti-Id activity, Idantirx . This drug has been shown to have potent anti-cancer action and is being tested for ocular use and other indications. The results with Idantirx confirm years of studies with mice lacking the Id genes and proteins." Dr. William Garland, CEO, added, "We have generated extensive data that establishes the ability of Idantirx to suppress key tumor promoting processes (growth, angiogenesis, cell migration) caused by the Id proteins. In these studies, Idantirx does not cause any apparent side effects probably because the Id proteins, the target of Idantirx , are very rarely found in healthy tissue.”